HomeBiotechnologyEditas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients ...
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease